Here’s whether Bristol-Myers Squibb Co. (BMY) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+2.52% over 10 days); RSI 56 — healthy momentum range; strong 1-year return of +33.5%; 3-month momentum positive (+12.0%). Currently 6.3% off its 52-week high. Score: +7/7.
BMY is in a confirmed uptrend, trading above both its 50-day ($59.58) and 200-day ($56.60) moving averages. An RSI of 55.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +33.5% compares to +20.4% for SPY (beat the market by 13.1%).
$10,000 invested 1 year ago→ $13,351 today
vs. S&P 500 (SPY) — same period beat market by 13.1%
1-Year Price Chart
Daily candles
MA-50MA-200UpDown
Signal Check
✓Above 200-day MA ($56.60)
✓Above 50-day MA ($59.58)
✓RSI(14) neutral zone (30–70) — currently 55.8
✓Positive return (+33.5%)
✓Within 10% of period high (−6.3%)
Period Range $63.83
$42.52$68.10
RSI (14) 55.8
0 · OversoldOverbought · 100
Key Metrics
Price$63.83
Period Return+33.5%
Period High$68.10
Period Low$42.52
Drawdown−6.3%
MA-50$59.58
MA-200$56.60
RSI (14)55.8
Avg Volume (30d)11.7M
vs. SPYbeat by 13.1%
Return Rank#377 of 1252
Trend Signals
Price is above the 200-day moving average ($56.60)